We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 848

No guidance on scope of Bolar exemption as CJEU case C-66113 is closed
  • Dehns
  • European Union, Germany
  • December 3 2014

At long last, a referral to the Court of Justice of the EU (CJEU) was expected to clarify the scope of the European Bolar exemption with regard to


A consistently broad interpretation of "health claim" emerges in Europe
  • Taylor Wessing
  • European Union, Germany
  • April 30 2014

A decision recently handed down by the German Federal Court of Justice (Bundesgerichtshof - BGH) has confirmed the broad interpretation of the term


Stem cell news - EPO revokes ‘Brüstle’ patent and new CJEU referral on the patentability of parthenotes
  • D Young & Co
  • European Union, Germany, United Kingdom
  • June 4 2013

As previously reported in this newsletter (1), the question of the patentability of technology based on the use of human embryonic stem cells (hESC


New draft German law regarding anti-corruption in the healthcare sector
  • Hogan Lovells
  • Germany
  • February 4 2015

We would like to inform you that the German Ministry of Justice recently provided a new draft anticorruption law explicitly referring to the


Johnson & JohnsonNovartis another challenge to pay for delay: is this ever permissible?
  • Bryan Cave LLP
  • European Union, France, Germany, Italy, United Kingdom
  • January 14 2014

In the latest challenge to so-called “pay for delay” or “reverse payment” agreements, on 10 December 2013, the European Commission fined the


Bolar exemption - C-66113 - Astellas Pharma referral to the CJ
  • D Young & Co
  • European Union, Germany
  • April 7 2014

The Dusseldorf Court of Appeal has referred questions to the Court of Justice of the European Union (CJ) concerning the applicability of the


Associations calls for better protection of consumers in draft law on e-health
  • Squire Patton Boggs
  • Germany
  • March 23 2015

The Federation of German Consumer Organisations (Vebraucherzentrale Bundesverband (VZBV)) recently criticized the new draft law on e-health stating


Germany
  • SKW Schwarz Rechtsanwälte
  • Germany
  • February 13 2015

By law, a company can market a pharmaceutical product only once it has received marketing authorisation. Marketing authorisation can be obtained


Horizonte 2015
  • Norton Rose Fulbright LLP
  • European Union, Germany
  • February 11 2015

Seit Mitte 2013 können wir durch unsere Präsenz auch im US-amerikanischen Markt ein globales Profil anbieten, das den vielfältigen Anforderungen


Infringement of second medical use patents
  • Taylor Wessing
  • Germany, United Kingdom
  • March 4 2015

With the increase in off-label prescribing in Europe, some argue that the carve-outs used by generic firms (see "Skinny labelling and the blue box